FX-06 (Fibrin-derived peptide Bβ15-42) is derived from the fibrin Bbeta chain and interacts with VE-cadherin to inhibit leukocyte transmigration while initiating VE-cadherin-mediated signaling pathways. This compound is utilized in researching ischemia/reperfusion injury and Dengue shock syndrome (DSS) [1] [2] [4].

FX-06 (50 μM, 3 days) inhibits D2HG synthesis in HEK-293T cells expressing mutant IDH1 R132H [2].

FX06, administered intravenously at 2.4 mg/kg as a bolus, notably enhances pulmonary and circulatory function in a porcine model of hemorrhagic shock and reperfusion [3]. The same dosage, given intraperitoneally twice daily, increases survival rates and mitigates capillary leakage in Dengue shock syndrome mouse models [4]. When administered at 3.6 mg/kg intravenously, FX06 safeguards against ischemia/reperfusion (I/R)-induced renal damage in mice, promoting epithelial cell proliferation and facilitating tissue repair [5].